🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

John Wright

University of California, Berkeley

ORCID: 0000-0002-5557-6168

Social SciencesPsychologyBiochemistry, Genetics and Molecular BiologyArts and Humanities

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial”.

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

The Lancet(2021)10.1016/s0140-6736(21)00152-5

N/A

6.9DataRank · unranked

283 citations

Catherine M. Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y.C. Heng +15 more

Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease

Gastroenterology(2020)10.1053/j.gastro.2020.03.039

N/A

5.7DataRank · unranked

240 citations

Clara Yzet, Peter Bossuyt, Filip J. Baert, Thomas Vanasek, Geert D’Haens +34 more

Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5039

N/A

0.208DataRank · unranked

3 citations

Daniel M. Girardi, Amir Mortazavi, Primo N. Lara, Sumanta K. Pal, Biren Saraiya +15 more

Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5037

N/A

0.165DataRank · unranked

2 citations

Scot A. Niglio, Amir Mortazavi, Primo Lara, Sumanta K. Pal, Biren Saraiya +15 more

A phase II study of savolitinib (volitinib, AZD6094, HMPL-504) in subjects with MET amplified metastatic colorectal cancer (mCRC) detected by cell-free (cf)DNA.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.tps270

N/A

0DataRank · unranked

3 citations

Donna Niedzwiecki, Christy Arrowood, Nancy Garett-Mead, Rebecca J. Nagy, Richard B. Lanman +4 more

Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.07.031

N/A

0DataRank · unranked

31 citations

Christina M. Annunziata, John L. Hays, Liang Cao, Peter L. Choyke, Minshu Yu +8 more

Criminal arrests associated with reduced regional brain volumes in an adult population with documented childhood lead exposure

Environmental Research(2021)10.1016/j.envres.2021.111559

N/A

0DataRank · unranked

15 citations

Kim N. Dietrich, John Wright, Mekibib Altaye, Kim M. Cecil, Travis Beckwith

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.270

N/A

0DataRank · unranked

9 citations

Catherine M. Tangen, Ian M. Thompson, Naomi B. Haas, Daniel J. George, Daniel Yick Chin Heng +15 more